June 2019
- US FDA grants priority review to rituximab in combination with glucocorticoids for treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in children from age two years
- The association between maternal body mass index and child obesity: A systematic review and meta-analysis
- Adjusting the dose in paediatric care: dispersing four different aspirin tablets and taking a proportion
- fluticasone propionate/formoterol fumarate (Flutiform®) accepted for use within NHSScotland in children aged 5-12 years
- fingolimod (Gilenya®) accepted for use within NHSScotland in children aged 10-18 years
- Increasing influenza immunisation uptake among children – leaflet for general practice
- Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial
- Childhood Asthma Management in Primary Care – Implementation of Exhaled Nitric Oxide and Spirometry Testing (CHAMPIONS study)
- Should measles vaccination be compulsory?
- Pivotal phase III ARTEMIS trial reports consistent safety and efficacy of AR101 in children and adolescents with peanut allergy
- Rotavirus vaccine (Rotarix®): patient group direction (PGD) template (updated)
- MenACWY vaccine (Menveo® or Nimenrix®): patient group direction (PGD) template (updated)
- Transition between child and adult services for young people with attention-deficit hyperactivity disorder (ADHD): findings from a British national surveillance study
- Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder
- Modernising vaccine surveillance systems to improve detection of rare or poorly defined adverse events
- Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT
May 2019
- May BNF/BNFC eNewsletter
- Prevalence of maternal mental illness among children and adolescents in the UK between 2005 and 2017: a national retrospective cohort analysis
- US FDA approves gene therapy onasemnogene abeparvovec-xioi to treat paediatric patients (less than 2 years of age) with spinal muscular atrophy (SMA)
- Maternal and fetal outcomes in pregnancies complicated by Marfan syndrome
- Interventions to improve the mental health of children and young people with long-term physical conditions: linked evidence syntheses
- Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder—outcome measures beyond symptom control and clinical trials
- Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study
- Association of Changes in Air Quality With Incident Asthma in Children in California, 1993-2014
- Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery
- Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps
- US FDA approves nasal midazolam for acute repetitive seizures
- Fragmin (dalteparin sodium) approved by FDA as first anticoagulant for children
- Hepatic late adverse effects after antineoplastic treatment for childhood cancer
- Long‐term antibiotics for preventing recurrent urinary tract infection in children
- Probiotics for the prevention of paediatric antibiotic‐associated diarrhoea
- The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study
- Association of Gestational Weight Gain With Adverse Maternal and Infant Outcomes
- New Product: Sprycel (dasatinib) 10 mg/mL powder for oral suspension
- Epanutin (phenytoin) 50mg Infatabs (Pfizer) supply issue
- Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: national cohort study
- US FDA approves amifampridine for children with Lambert-Eaton myasthenic syndrome
- Health Secretary considers ‘all options’ to boost vaccine uptake
- Revised SPC: Bramitob (tobramycin) Nebuliser Solution
- New Product: Sprycel (dasatinib) 10 mg/mL powder for oral suspension
- Interventions for infantile seborrhoeic dermatitis (including cradle cap)
- Conference abstract – RCT reports cannabidiol (CBD) reduces convulsive seizure frequency in children and adolescents with Dravet syndrome
April 2019
- 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis
- Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety
- Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer
- Liraglutide in Children and Adolescents with Type 2 Diabetes
- UNICEF reports over 20 million children worldwide missed out on measles vaccine annually in past 8 years creating a pathway to current global outbreaks
- BioMarin confirms all UK patients who took part in clinical trials of sapropterin dihydrochloride (Kuvan) for phenylketonuria (PKU) will be able to access drug after trials end
- Association of Exposure to Infections in Childhood With Risk of Eating Disorders in Adolescent Girls
- Revised SPCs: ORENCIA (abatacept) 50, 87.5 and 125mg solution for injection (pre-filled syringe)
- Revised SPC: Epistatus 10 mg Oromucosal Solution – Carer instructions for administration updated
- Brivaracetam add‐on therapy for drug‐resistant epilepsy
- Innovative child malaria vaccine to be tested in Malawi
- Maternal Glycemic Control in Type 1 Diabetes and the Risk for Preterm Birth: A Population-Based Cohort Study
- Hepatitis C virus infection in children and adolescents
- Hepatitis B virus infection in children and adolescents
- UK immunisation schedule: the green book, chapter 11 (updated)
- Probiotics to prevent infantile colic
- Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme
- Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial
- Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial
- Rapid Over Infusion of Parenteral Nutrition (PN)- update to Patient Safety Alert NHS/PSA/W/2017/005 issued Sept 2017
- NHS staff and parents to gain access to crucial child health information
- Hepatitis virus infection in children and adolescents
- Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study
- Saving Babies’ Lives Version Two: A care bundle for reducing perinatal mortality
- Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT
- Dasotraline in Children with Attention-Deficit/Hyperactivity Disorder: A Six-Week, Placebo-Controlled, Fixed-Dose Trial
- Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial
- Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study
- Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation
- NIHR Signal: Does an antibacterial milk protein reduce infection in premature babies?
- Specialist neonatal respiratory care for babies born preterm (NG 124) – guidance
- New presentation: Fycompa (perampanel) 0.5 mg/ml oral suspension
- February BNF/BNFC eNewsletter
March 2019
- Transforming children’s services
- Association of Prenatal Cannabis Exposure With Psychosis Proneness Among Children in the Adolescent Brain Cognitive Development (ABCD) Study
- Antibiotic treatment for newborns with congenital syphilis
- Current and Future Challenges for Children Across the World
- NHS England Specialised Commissioning document: Selective Dorsal Rhizotomy for treatment of spasticity in cerebral palsy
- Chloramphenicol: is it safe in breastfeeding?
- Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
- High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years
- NHS and Vertex remain deadlocked over price of Orkambi (lumacaftor/ivacaftor)
- Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA)
- Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial
- Association of Atopic Dermatitis With Sleep Quality in Children
- First 1000 days of life
- A priori choice of neuraxial labour analgesia and breastfeeding initiation success: a community-based cohort study in an Italian baby-friendly hospital
- What is the sodium content of medicines?
- First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
- Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial
- Postoperative epidural analgesia versus systemic analgesia for thoraco‐lumbar spine surgery in children
- Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study
- Theophylline and aminophylline for prevention of acute kidney injury in neonates and children: a systematic review
- Biologics for paediatric severe asthma: trick or TREAT?
- School‐based self‐management interventions for asthma in children and adolescents: a mixed methods systematic review
February 2019
- Cardiovascular Risk Reduction in High-Risk Pediatric Patients: A Scientific Statement From the American Heart Association
- Pertussis (whooping cough)
- Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial
- Universal antenatal screening for group B streptococcus may cause more harm than good
- Topiramate for juvenile myoclonic epilepsy
- Neurodevelopmental outcome at 5 years of age after general anaesthesia or awake-regional anaesthesia in infancy (GAS): an international, multicentre, randomised, controlled equivalence trial
- Spina bifida: information for parents
- Althea to launch cannabis based products in the UK
- Eisai submits application to extend licence of perampanel to include treatment of paediatric patients with epilepsy
- Enterovirus as trigger of coeliac disease: nested case-control study within prospective birth cohort
- Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis
- Child abuse and neglect- quality standard (QS179)
- Cases of measles in Europe at highest rate in a decade due to growing number of areas where parents are refusing vaccination for their children
- European Commission approves dasatinib in combination with chemotherapy for treatment of paediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukaemia
- Adoption of Peristeen at Alder Hey Children’s Hospital
- New product: OZALIN (midazolam) 2 mg/ml oral solution in single-dose container
- Education Secretary announces that up to 370 schools in England will take part in a series of trials testing different approaches to supporting young people’s mental health
- January 2019 BNF/ BNF C eNewsletter
- Childhood obesity: time for action report – government response
- European CHMP recommends license extension of abatacept (Orencia) for treatment of olyarticular juvenile idiopathic arthritis
- European CHMP recommends atazanavir (Atazanavir Krka) for treatment of HIV-1 in adults and children 6 years of age and older
- Mental health trial launches in schools in England
January 2019
- Limited evidence for non-drug treatment of childhood ADHD: DTB Select summary
- Seizures and quinolone antibiotics in children: a systematic review of adverse events
- Early access to medicines scheme (EAMS) scientific opinion: Dupilumab as a treatment of adolescent patients between 12 and 18 years of age with severe atopic dermatitis for whom the available systemic therapies are not suitable
- Depression in children and young people: identification and management – DRAFT guidance
- Children and young people exposed prenatally to alcohol
- Determining the reasons for poorly controlled asthma in an adolescent
- European Commission approves paediatric license extension of Orkambi (lumacaftor/ivacaftor) for cystic fibrosis
- Mental health services for children and young people
- PCV (13-valent, adsorbed): patient group direction (PGD) template
- Flutiform (fluticasone/ formoterol) approved in EU for treatment of children with asthma aged five years and over
- Tiotropium (Spiriva® Respimat®) for asthma in paediatric patients
- Sedation of children undergoing dental treatment
- Recombinant growth hormone therapy for cystic fibrosis in children and young adults
- Maternal probiotic supplementation for prevention of morbidity and mortality in preterm infants
- Enteral lactoferrin supplementation for very preterm infants: a randomised placebo-controlled trial
- Childhood cancer burden: a review of global estimates
- Revised SPC: Ravicti (glycerol phenylbutyrate) 1.1 g/ml oral liquid
- Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (ages 2 years and above): Clinical Commissioning Policy
December 2018
- Paediatric extrapolation: A necessary paradigm shift
- Which medicines require extra care when switching between liquid and tablet/capsule formulations?
- BNF/BNFC eNewsletter December 2018
- Notification of the discontinuation of Zovirax (aciclovir) eye ointment 3% 4.5g
- Antibiotic and acid-suppression medications during early childhood are associated with obesity
- Hydrocortisone muco-adhesive buccal tablets: should not be used off-label for adrenal insufficiency in children due to serious risks
- Single, short-time exposure to heat in a car during sunny day can decrease epinephrine concentration in autoinjectors: a real-life pilot study
- Ketogenic diets for drug‐resistant epilepsy
- Oral lidocaine-containing products for infant teething: only to be available under the supervision of a pharmacist
- Timing of dornase alfa inhalation for cystic fibrosis
- Protocol‐directed sedation versus non‐protocol‐directed sedation in mechanically ventilated intensive care adults and children
- Melatonin in children with cancer
- Maternal immunisation to improve the health of HIV-exposed infants
- Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink
November 2018
- Ivacaftor approved in the EU to treat patients aged 12 to ≤24 months with certain mutations in the CFTR gene
- Early intervention for depression in young people: a blind spot in mental health care
- Manufacturers report positive outcomes for triple combination therapy in cystic fibrosis in preliminary data from phase III trials
- Children’s Commissioner for England publishes new analysis on the provision of children’s mental health services in England
- Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis
- Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children
- Help make medicines safer: report suspected side effects in children and during pregnancy
- European CHMP recommends approval of two paediatric formulations of lumacaftor / ivacaftor (Orkambi)
- AR101 Oral Immunotherapy for Peanut Allergy
- European CHMP endorses suspension or restrictions of quinolone and fluoroquinolone antibiotics due to disabling and potentially permanent adverse effects
- Childhood Immunisation CCG/GP Practice level coverage statistics 2017-18 (Management Information)
- European Medicines Agency issues guidance on safety monitoring of medicines used in children
- NIHR Signal: Oral steroids do not help hearing for children with glue ear
- Sildenafil (Revatio and Viagra): reports of persistent pulmonary hypertension of the newborn (PPHN) following in-utero exposure in a clinical trial on intrauterine growth restriction
- Cannabis-based products for medicinal use: Guideline scope
- Heliox for croup in children
- Supporting public health: children, young people and families
- Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970–99: a report from the Childhood Cancer Survivor Study cohort
- Oral steroids for hearing loss associated with otitis media with effusion in children aged 2 8 years: the OSTRICH RCT
- Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis
- New product: Symkevi (100mg tezacaftor/ 150mg ivacaftor) film coated tablets
- Cannabis based drugs: how will they be used in practice?
- European Commission approves Symveki (tezacaftor/ivacaftor) for treatment of selected patients with cystic fibrosis
- Chief medical officer (CMO) urges parents to get children vaccinated and ignore “social media fake news” about MMR vaccine
- Pharmacological and non-pharmacological interventions for non-respiratory sleep disturbance in children with neurodisabilities: a systematic review
- Cannabis-based products for medicinal use: Guidance to clinicians
- The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use in humans ‘specials’
- Nebulised hypertonic saline for cystic fibrosis
- Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants
October 2018
- Pregnancy problems: a guide for pharmacy
- US FDA approves sodium oxybate (Xyrem®) oral solution for treatment of cataplexy or excessive daytime sleepiness in paediatric narcolepsy patients
- GPhC statement on supplying valproate safely to women and girls
- Royal Pharmaceutical Society (RPS) practical guide to support pharmacist independent prescribers
- Maternal paracetamol intake and fetal ductus arteriosus constriction or closure: a case series analysis
- Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination
- Adding emollient bath additives to standard eczema management for children with eczema: the BATHE RCT
- October 2018 BNF/BNFC eNewsletter
- Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term
- European CHMP recommends approval of extension to existing indication of ivacaftor (Kalydeco)
- VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
- VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
- Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis
- Maternal Antibiotic Use During Pregnancy and Type 1 Diabetes in Children: A National Prospective Cohort Study
- Assessment and initial management of suspected behavioural insomnia in pre-adolescent children
- β-Blocker Use in Pregnancy and the Risk for Congenital Malformations: An International Cohort Study
- Tuberculosis susceptibility and protection in children
- Strategies to improve detection and management of human parechovirus infection in young infants
- NHS England – Junior Epipen shortage
- Revised SPC: Isentress (raltegravir) 100 mg Granules for Oral Suspension – extension to neonates
- Specialist neonatal respiratory care for babies born preterm
- Needle size for vaccination procedures in children and adolescents
- Glucocorticoids for croup in children
- Improving children and young people’s mental health services
- Transdermal fentanyl patches: life-threatening and fatal opioid toxicity from accidental exposure, particularly in children
- Improving children and young people’s mental health services
- Does melatonin improve sleep in children with neurodevelopmental disorders?
- Lipid‐based nutrient supplements for maternal, birth, and infant developmental outcomes
- Burosumab for treating X-linked hypophosphataemia in children and young people – guidance (HST8)
- Coeliac disease in children
- Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
September 2018
- Boosting the development of medicines for children
- Poor Metabolic Control in Children and Adolescents With Type 1 Diabetes and Psychiatric Comorbidity
- Positive Phase II data for once-weekly growth hormone analogue (somapacitan) in childhood growth hormone deficiency
- Meningitis report: Spotting a seriously ill child
- Ketorolac for postoperative pain in children
- September BNF/BNFC eNewsletter
- Medical and surgical interventions for the treatment of urinary stones in children
- Amoxicillin–clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial
- Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
- Long-term developmental effects of withholding parenteral nutrition for 1 week in the paediatric intensive care unit: a 2-year follow-up of the PEPaNIC international, randomised, controlled trial
- Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study
- Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders
- Impact of antibiotics for children presenting to general practice with cough on adverse outcomes: secondary analysis from a multicentre prospective cohort study
- Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies
- Bronchiectasis in children: diagnosis and treatment
- Tisagenlecleucel to be made available on NHS for children and adults up to age 25 years for B cell acute lymphoblastic leukaemia
- Burosumab for treating X-linked hypophosphataemia in children and young people – Final appraisal determination
- The Good Childhood Report 2018
- Treatment of extravasation injuries in infants and young children: a scoping review and survey
- An overview of the EU’s orphan designation programme
- Face‐to‐face interventions for informing or educating parents about early childhood vaccination
- Clonazepam add‐on therapy for refractory epilepsy in adults and children
- Revised SPC: Blincyto (blinatumomab) solution
August 2018
- Mepolizumab approved in EU for treatment of paediatric patients with severe eosinophilic asthma
- Paracetamol (acetaminophen) for patent ductus arteriosus (a blood vessel necessary for fetal survival) in preterm and low birth weight infants
- Interventions for infantile haemangiomas of the skin
- Honey for acute cough in children
- BNF and BNF for Children Update: August 2018
- Local anaesthetics and regional anaesthesia versus conventional analgesia for preventing persistent postoperative pain in adults and children
- National Paediatric Diabetes Audit
- Perinatal Marijuana Use and the Developing Child
- Paediatric intensive care and neonatal intensive care airway management in the United Kingdom: the PIC‐NIC survey
- Video on valproate use during pregnancy to support healthcare professionals
- The Risk of Offspring Psychiatric Disorders in the Setting of Maternal Obesity and Diabetes
- Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association
- Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Information System): a population-based study
- Vitamin D Supplementation in Pregnancy and Lactation and Infant Growth
- FDA approve lumacaftor/ivacaftor (Orkambi) Cystic Fibrosis for Children Ages 2-5 Years in US
- Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study
- Effect of a Responsive Parenting Educational Intervention on Childhood Weight Outcomes at 3 Years of Age: The INSIGHT Randomized Clinical Trial
- NIHR Signal Adding emollients to the bath unlikely to help children with eczema
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis
- Revised SPC: Rotarix (Human rotavirus, RIX4414 strain, live, attenuated) Oral Applicator
- Revised SPC: Briviact (brivaracetam) 10 mg/ml oral solution – licensed from 4 years of age
- Safety and Side Effects of Rifampin versus Isoniazid in Children
July 2018
- Association Between the New York Sepsis Care Mandate and In-Hospital Mortality for Pediatric Sepsis
- BNF and BNFC Update: July 2018
- Revised SPC: Gentamicin Intrathecal 5mg/ml – no longer contra-indicated in under one year of age
- Clarification of the doses at extremes of body-weight statement for vancomycin in BNF and BNF for Children
- Antidepressant prescriptions for children on the rise
- In use product safety assessment report for intravenous paracetamol in paediatrics
- Scientific Advisory Committee on Nutrition (SACN) publishes report on ‘Feeding in the first year of life’
- Perinatal Marijuana Use and the Developing Child
- Recurrent lower respiratory tract infections in children
- Periconception glycaemic control in women with type 1 diabetes and risk of major birth defects: population based cohort study in Sweden
June 2018
- NIHR Signal: Oral ibuprofen may be an option for closing patent ductus arteriosus in premature babies
- Xenidate XL (methylphenidate) Prolonged-release Tablets: Checklist before prescribing
- MHRA will continue to monitor safety of opioid patches after baby’s death
- European CHMP recommends approval of tisagenlecleucel (Kymriah) for acute lymphoblastic leukaemia (ALL) and diffuse large B cell lymphoma (DLBCL)
- Revised SPC: Curosurf (poractant alfa)
- Public Health England and Disney UK launch Change4Life Train Like A Jedi programme
- June BNF/BNFC eNewsletter
- Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes
- Perceptions of future health and cancer risk in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study
- Metformin exposure in first trimester of pregnancy and risk of all or specific congenital anomalies: exploratory case-control study
- UK to review medical cannabis policy
- Maternal and infant outcomes associated with lithium use in pregnancy: an international collaborative meta-analysis of six cohort studies
- The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates
- Idiopathic nephrotic syndrome in children
- Burosumab for treating X-linked hypophosphataemia in children and young people: Evaluation consultation
- Spiriva (tiotropium) Respimat licensed in UK for treatment of asthma in patients aged six years and above
- Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial
- Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study
- At-risk children with asthma (ARC): a systematic review
- European CHMP recommends approval of adalimumab biosimilars (Halimatoz, Hefiya and Hyrimoz)
- European CHMP recommends approval of nitisinone (Nityr) for treatment of hereditary tyrosinemia type 1
May 2018
- Nonpharmacologic Treatments for Attention-Deficit/Hyperactivity Disorder: A Systematic Review
- Association Between Vitamin D Supplementation During Pregnancy and Offspring Growth, Morbidity, and Mortality – A Systematic Review and Meta-analysis
- Mass chemoprophylaxis for control of outbreaks of meningococcal disease
- Adolescent affective symptoms and mortality
- Higher versus lower amino acid intake in parenteral nutrition for newborn infants
- Beta-blockers for prevention and treatment of retinopathy of prematurity in preterm infants
- Important considerations for interpreting biochemical tests in children
- US FDA accepts supplemental biologics license application for prophylactic and paediatric use of Coagadex® (Coagulation Factor X, Human) for treatment of hereditary factor X deficiency
- Antibiotics at the time of removal of central venous catheter to reduce morbidity and mortality in newborn infants
- Immunoglobulin for alloimmune hemolytic disease in neonates
- European Medicines Agency investigating new study suggesting increased risk of neural tube defects in infants born to women who took dolutegravir at conception
- Systemic corticosteroids for acute otitis media in children
- Developmental follow-up of children and young people born preterm – quality standard (QS169)
- Cystic fibrosis – quality standard (QS168)
- Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease
- The use of complementary and alternative medicines during breastfeeding: results from the Herbal supplements in Breastfeeding InvesTigation (HaBIT)
- US FDA approves oral brivaracetam for the treatment of partial-onset (focal) seizures in paediatric patients
- Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer Clinical, Neurophysiological, Functional, and Patient-Reported Outcomes
- Prophylactic vitamin K for the prevention of vitamin K deficiency bleeding in preterm neonates
- FDA expands approval of fingolimod (Gilenya) to treat multiple sclerosis in paediatric patients
- Which weak opioids can be used during breastfeeding? Considering the evidence for codeine, dihydrocodeine, and tramadol
- Prevalence estimates and risk factors for early childhood wheeze across Europe: the EuroPrevall birth cohort
- Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
- Which oral antihistamines are safe to use whilst breastfeeding?
- Vaccines for preventing influenza in healthy children
- Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis
- NIHR Signal: Domperidone increases breast milk production in mothers of premature babies
- Can mothers breastfeed after a medical termination of pregnancy?
- Breastfeeding and lithium: is breast always best?
- Inhaled mannitol for cystic fibrosis
- Emollient bath additives for the treatment of childhood eczema (BATHE): multicentre pragmatic parallel group randomised controlled trial of clinical and cost effectiveness
- Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?
- Effect of Atropine With Propofol vs Atropine With Atracurium and Sufentanil on Oxygen Desaturation in Neonates Requiring Nonemergency Intubation: A Randomized Clinical Trial
- Extended-release methylphenidate – An updated review of the pharmacokinetic profiles of available preparations
- Prostaglandin E1 for maintaining ductal patency in neonates with ductal-dependent cardiac lesions
For older news click here